Understand the source comparison
Comparison of Research Peptides for Connective Tissue Injury
The following comparison table evaluates the primary research peptides investigated for tendon and connective tissue repair based on mechanism of action, documented preclinical effects, typical research protocols, and key considerations for laboratory use. BPC
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following comparison table evaluates the primary research peptides investigated for tendon and connective tissue repair based on mechanism of action, documented preclinical effects, typical research protocols, and key considerations for laboratory use.
- BPC-157
- Stabilizes nitric oxide pathways; modulates VEGF and growth factor expression during inflammation-to-proliferation transition
- Enhanced angiogenesis, fibroblast migration, collagen organization; 30–40% faster healing in rodent tendon models
- 200–500 mcg/day subcutaneous injection in animal models; human research uses extrapolated dosing
- Most studied for gastric and tendon injury; gastric origin peptide with systemic tissue repair effects
- Best-evidenced peptide for early-phase tendon repair; wide therapeutic index in preclinical models
- TB-500 (Thymosin Beta-4)
- Binds G-actin to promote cell migration; upregulates MMPs for matrix remodeling; enhances endothelial differentiation
- Increased tensile strength, reduced fibrosis, accelerated angiogenesis; effective in cardiac and skeletal muscle injury models
- 2–10 mg twice weekly in research animals; dosing scaled by body weight
- Naturally occurring in all nucleated cells; synthetic version replicates endogenous molecule
- Strongest evidence for proliferative-phase repair and angiogenesis; complements BPC-157 timing
- GHK-Cu (Copper Peptide)
- Copper ion carrier that stimulates collagen synthesis via TGF-beta pathway; antioxidant activity
- Promotes wound closure, increases collagen and glycosaminoglycan production; studied primarily in dermal wounds
- 1–5 mg applied topically or injected locally in wound models
- Copper bioavailability is dose-limiting; primarily studied in skin rather than deep tendon
- Effective for surface-level tissue repair; less evidence for deep connective tissue injury
- IGF-1 LR3
- Long-acting insulin-like growth factor-1 analog; stimulates protein synthesis and satellite cell proliferation
- Increases muscle hypertrophy and recovery; some evidence for tendon fibroblast proliferation
- 20–100 mcg/day in animal models; highly anabolic at muscle-tendon junctions
- Potent anabolic; primary use in muscle injury research rather than isolated tendon injury
- Useful in muscle-tendon junction injuries; limited standalone tendon repair evidence
- BPC-157 and TB-500 dominate tendon injury research because their mechanisms align precisely with the biological phases of tendon healing—inflammation modulation and proliferative support, respectively. GHK-Cu and IGF-1 LR3 offer secondary support but lack the depth of tendon-specific preclinical data.